Published 6 months ago • loading... • Updated 6 months ago

Lilly Pill Helps Maintain Weight Loss in Trial After Switch From Injectables

On Thursday, Eli Lilly & Co. said orforglipron, the daily oral GLP-1 pill, helped patients maintain most weight loss after switching from Wegovy and Zepbound, with the ATTAIN-MAINTAIN trial meeting its primary endpoint.
Many patients who stop injectable GLP-1 shots often regain substantial weight, and Eli Lilly & Co. recently filed for FDA approval of orforglipron, receiving a priority review voucher in November.
The phase three trial followed more than 300 patients after 72 weeks of injections, then randomized them to orforglipron or placebo for 52 weeks, with weight maintained near 95.9 kg despite small rebounds.
Lilly said overall safety and tolerability matched prior studies, with no liver safety issues observed and discontinuation rates 4.8% and 7.2% due to generally mild-to-moderate gastrointestinal side effects.
Analysts expect Lilly may capture a 60% share or roughly $13.6 billion of the 2030 market, with pills priced at $150 per month, while Novo Nordisk's oral may reach market first.

Insights by Ground AI

25 Articles

Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Quick Read Eli Lilly (LLY) submitted an FDA application for orforglipron. The once-daily oral pill maintained weight loss after patients switched from injections. Lilly’s Zepbound achieved 20.2% average weight loss over 72 weeks versus 13.7% for Novo Nordisk‘s Wegovy in a Phase 3 trial. Novo Nordisk’s higher-dose oral semaglutide could be approved by year-end. Lilly’s orforglipron approval may come in early 2026. If you’re focused on picking…

6 months ago·New York, United States

Read Full Article